Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study

C. Koopal, K. Retterstol, B. Sjouke, G. K. Hovingh, E. Ros, J. de Graaf, R. P. F. Dullaart, S. Bertolini, F. L. J. Visseren*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Familial dysbetalipoproteinemia (FD), also known as type III hyperlipoproteinemia, is a genetic dyslipidemia characterized by elevated very low density lipoprotein (VLDL) and chylomicron remnant particles that confers increased risk of cardiovascular disease (CVD). The objective of this study was to evaluate the prevalence of vascular risk factors, CVD, lipid values, treatment and lipid targets in patients with FD across Europe.

Methods: This cross-sectional study was performed in 305 patients with FD from seven academic hospitals in four European countries. Information was collected from clinical records.

Results: Patients mean (+/- standard deviation) age was 60.9 +/- 14.4 years, 201 (66%) were male, 69 (23%) had diabetes mellitus (DM) and 87 (29%) had a prior history of CVD. Mean body mass index was 28.5 +/- 5.0 kg/m(2). Lipid-lowering medication was used by 227 (74%) patients (27% usual dose (theoretical low-density lipoprotein cholesterol (LDL-C) reduction 40%)). Non high-density lipoprotein cholesterol (non-HDL-C) levels below treatment target (

Conclusion: The majority of FD patients had non-HDL-C levels above the treatment target of 3.3 mmol/L. Intensive dose lipid-lowering medication was used by only half of the patients, leaving them at increased cardiovascular risk.

Original languageEnglish
Pages (from-to)90-97
Number of pages8
JournalAtherosclerosis
Volume240
Issue number1
DOIs
Publication statusPublished - May 2015

Keywords

  • Familial dysbetalipoproteinemia
  • Hyperlipoproteinemia type III
  • Lipids
  • Dyslipidemias
  • Drug therapy/hypolipidemic drugs
  • Cardiovascular disease
  • Risk factors
  • DENSITY-LIPOPROTEIN CHOLESTEROL
  • HUMAN APOLIPOPROTEIN-E
  • TREATMENT PANEL-III
  • REMNANT CHOLESTEROL
  • HEART-DISEASE
  • APO-E
  • HYPERLIPOPROTEINEMIA
  • HYPERLIPIDEMIA
  • MANAGEMENT
  • PLASMA

Fingerprint

Dive into the research topics of 'Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study'. Together they form a unique fingerprint.

Cite this